法庭上所提出的數位證據,勇闖太空園游會616如監視畫面、勇闖太空園游會616網路留言,因為容易被竄改失去證據力?,F在區塊鏈的技術將能幫助民眾自保。由國內數位鑒識權威、鑒真數位轉投資的區塊科技公司,今天(18日)宣布推出自主研發的「區塊鏈存證王APP」,將有效確保證據的真實性與有效性。#請聽記者楊仁翔、楊文君的採訪報導#

當發生行車糾紛,民眾通常會拿出手機拍照存證,但哪些刮痕是當下發生,哪些是之前就有的,常因證據不足,審理起來曠日費時。

資深法律人、達文西個資暨高科技法律事務所所長葉奇鑫就指出,關鍵就在于數位檔案易損毀或遺失、易被竄改、有效性難以被認可這三大疑慮,法官通常只會當成是輔助證據。他說:『(原音)對方律師就會說,這是他自己拍的、這可能有變造、偽造,這時法官就會陷入一個難題,因為他沒辦法決定這是不是變造、偽造?!?/p>

為有效解決此問題,區塊科技公司自主研發出「區塊鏈存證王APP」,只要下載到手機,就能利用里面的拍照、錄影、錄音、螢幕錄影截圖等功能留下證據,運用區塊鏈不可竄改、不可毀損等特點,來保存數位證據的原始性。區塊科技股份有限公司執行長黃敬博說:『(原音)我相信這個將來會是一個很剛需的需求(剛性需求),因為每個人一定都會有創作,但你不知道這個創作怎么保護好,你今天一個idea,結果被別人聽到拿去申請專利,偷你idea還來告你?!?/p>

黃敬博舉例,現在網購盛行,當民眾發現受騙而提告時,網頁卻往往已遭撤換,但若將證據上鏈保存,便可讓不肖商家無所遁形。另外,在FB、LINE常見的網路霸凌,即使對方事后刪除留言或收回訊息,原告也能證實自己舉出的證據并非事后造假或合成。

黃敬博強調,目前第一階段會先聚焦在數位證據的存證與真偽辨識,未來會延伸至智慧財產權與重要商業文件的保護。

原始連結

" />
?
當前位置:首頁 > 隔離器 > 勇闖太空園游會6/16登場!16項天文游戲等你闖關 法庭上所提出的數位證據

勇闖太空園游會6/16登場!16項天文游戲等你闖關 法庭上所提出的數位證據

2020-09-21 03:41 [分度頭] 來源:西寧春旺照明公司


法庭上所提出的數位證據,勇闖太空園游會616如監視畫面、勇闖太空園游會616網路留言,因為容易被竄改失去證據力?,F在區塊鏈的技術將能幫助民眾自保。由國內數位鑒識權威、鑒真數位轉投資的區塊科技公司,今天(18日)宣布推出自主研發的「區塊鏈存證王APP」,將有效確保證據的真實性與有效性。#請聽記者楊仁翔、楊文君的採訪報導#

當發生行車糾紛,民眾通常會拿出手機拍照存證,但哪些刮痕是當下發生,哪些是之前就有的,常因證據不足,審理起來曠日費時。

資深法律人、達文西個資暨高科技法律事務所所長葉奇鑫就指出,關鍵就在于數位檔案易損毀或遺失、易被竄改、有效性難以被認可這三大疑慮,法官通常只會當成是輔助證據。他說:『(原音)對方律師就會說,這是他自己拍的、這可能有變造、偽造,這時法官就會陷入一個難題,因為他沒辦法決定這是不是變造、偽造?!?/p>

為有效解決此問題,區塊科技公司自主研發出「區塊鏈存證王APP」,只要下載到手機,就能利用里面的拍照、錄影、錄音、螢幕錄影截圖等功能留下證據,運用區塊鏈不可竄改、不可毀損等特點,來保存數位證據的原始性。區塊科技股份有限公司執行長黃敬博說:『(原音)我相信這個將來會是一個很剛需的需求(剛性需求),因為每個人一定都會有創作,但你不知道這個創作怎么保護好,你今天一個idea,結果被別人聽到拿去申請專利,偷你idea還來告你?!?/p>

黃敬博舉例,現在網購盛行,當民眾發現受騙而提告時,網頁卻往往已遭撤換,但若將證據上鏈保存,便可讓不肖商家無所遁形。另外,在FB、LINE常見的網路霸凌,即使對方事后刪除留言或收回訊息,原告也能證實自己舉出的證據并非事后造假或合成。

黃敬博強調,目前第一階段會先聚焦在數位證據的存證與真偽辨識,未來會延伸至智慧財產權與重要商業文件的保護。

原始連結

【財訊快報記者王宜弘報導】儘管上半年PC與伺服器市況略緩,登場16項影響業績動能,登場16項但超眾( 6230 )總經理郭大祺透露,6月已見到客戶提貨熱度拉升,對下半年業績展望審慎樂觀。

超眾週一(24日)召開股東會,順利通過去年財報與盈余分派案,去年合併營收共76.62億元,年增率8.4%,創歷史新高,EPS 6.9元,年增逾19%,今年將配發4.7元現金股利。

超眾前5月營收為32.42億元,較去年同期成長14.16%,其中,首季營收18.5億元,年增12.22%,稅后盈余1.41億元,年增3.3倍,EPS為1.63元,4、5月營收合計為13.9億元。


郭大祺表示,進入6月之后,客戶拉貨動能增強,推估除傳統季底做帳因素之外,上半年PC、伺服器市況較疲,悶太久,加上市場汰舊換新的剛性需求顯現所致。除了筆電與伺服器的動能提升之外,第二季傳出客戶砍單的手機業務,在6月也出現緩步提升的現象。


因此,他對于下半年營運發展抱持審慎樂觀的態度,今年逐季成長,全年業績再創新高可期。




【財訊快報記者王宜弘報導】儘管面臨英特爾CPU缺貨,天文游戲但仁寶( 2324 )第二季筆電出貨走揚,天文游戲法人預估出貨將有雙位數季增率,其中又以商用機種為大宗。不過,近年積極提升非PC業務,在平板、智慧穿戴裝置等出貨拉升之下,今年非PC業務占比將力拼4成。

仁寶週一(1日)股價在貿易戰休兵利多激勵臺股大漲之際,也收高0.74%或0.15元,來到20.5元價位。不過,相較同業在伺服器領域的布局均已收割,甚至成為營收獲利成長的主要動能,仁寶在伺服器領域仍處追趕格局,雖明年可見成果,但短期挹注之動能較少。

仁寶去年EPS在處分聯寶的獲利挹注之下,EPS突破2元,來到2.05元,今年商用筆電因換機潮持續而表現不錯,智慧裝置的成長動能也相當強勁,但少了業外加持,法人預估今年仁寶EPS約1.38元。該公司預計在7/15除息1.2元,以目前股價來看,殖利率約5.8%。




勇闖太空園游會6/16登場!16項天文游戲等你闖關

【財訊快報記者王宜弘報導】儘管美中貿易戰陰霾籠罩之下,你闖關客戶釋單態度略顯觀望,你闖關但IPC大廠凌華( 6166 )長期布局5G邊緣運算商機,內部持續看好成長動能。短期內,法人估6月因季底效應,業績將來到單季高峰,上半年EPS力拚1元,全年逾2元目標不變。

凌華近月股價在低檔整理之后,週五(5日)轉強,盤中最高來到39.45元價位,上漲1.3元或3.4%。該公司農曆年后因美中貿易戰與撤銷私募等因素,股價重挫2成,最低來到37元。

不過,凌華長期技術投資,其產品開發實力在業界普遍獲得肯定,董事長劉鈞近年積極布局5G時代下的邊緣運算商機,2015年底併入英國軟體商PT,強化軟硬整合實力,隨著5G商轉以及東京奧運腳步逼近,收割期在望。去年并為PC品牌大廠聯想(Lenovo)相中,雙方展開業務合作,甚至一度洽談入股策略聯盟,后雖擱置,但雙方業務合作持續。


儘管去年因市況不佳以及美中貿易戰沖擊,客戶延單,凌華營運降至谷底,但今年已然回升,去年第四季營收突破30億元創高,首季也有26.62億元,年增達17.8%,淡季不淡,EPS大幅回升到0.51元,法人預估第二季營收上探25億元,雖低于同期的26.83億元,但因零組件價格下滑、臺幣貶值助陣,毛利率較同期回升,加上費用維穩,上半年EPS力拚1元;隨著下半年旺季來臨,業績逐季上升,全年EPS逾2元目標不變,較去年翻倍。




【財訊快報記者王宜弘報導】儘管美運動服飾品牌大廠Under Armour近日下調北美營收展望,勇闖太空園游會616但法人看好成衣大廠儒鴻( 1476 )成長展望,勇闖太空園游會616預計下半年來自UA的訂單將成長3-5%。

UA近期雖下修2019北美營收展望,但據了解,UA將自2019年第四季起大幅整併供應鏈,目標在2020年要把前10大供應商的採購比重從55%提高到80%,目前所知臺系成衣供應商儒鴻以及平織布主力供應商得力( 1464 )受惠,后續來自UA的訂單比例均可望提升。

法人指出,UA縮減供應商的政策發酵下,儒鴻因應訂單增加,預計第四季將新增兩家外包協力廠商以緩解產能不足的壓力,并自2020年新增布料與成衣的產能,成長展望良好。


法人表示,儒鴻來自UA的業績占比約5-8%,預計下半年UA訂單將從上半年的同比持平表現,到下半年將有3-5%的成長。整體而言,儒鴻下半年將逐季成長,第四季達到高峰。




【財訊快報記者王宜弘報導】儘管根據Gartner甫出爐的第二季全球PC出貨調查報告顯示,登場16項上季出貨衰退幅度居前六大品牌之最,登場16項但宏( 2353 )週一(15日)引用IDC最新資料表示,其PC全球出貨以季增15%的強勁動能,于第二季站上全球個人電腦出貨的前四強。

此外,宏皏蝷犍哞PD與GfK報告指出,其品牌電競筆電在泛美市場傳捷,5月美國、巴西、阿根廷、智利、秘魯、哥倫比亞在內的泛美6國,皆登上電競筆電零售市占龍頭寶座。

其中,其電競筆電在哥倫比亞市場獲得51.7%的過半市占率,出貨量與去年同期相比成長率達311%;在智利的電競筆電市場于5月亦獲得44%的亮眼市佔率,持續領先當地市場。


根據Gartner的報告,宏眵臚G季PC出貨量年減14.4%,為全球前六大品牌衰退幅度最高者,市佔率5.4%,且仍落居蘋果(Apple)之后為第五大品牌。不過,宏痐犍呰DC的報告則指稱,其PC市佔率在第二季時已經躋身前四強。該公司近年將PC業務發展重心轉向具有市場利基的電競、超輕薄以及Chromebook等領域,并迭有斬獲,電競筆電表現亦突出,今年也切入創作者筆電(Creator PC),并推出次品牌「ConceptD」專責應戰。




勇闖太空園游會6/16登場!16項天文游戲等你闖關

【財訊快報記者王宜弘報導】儘管6月獲利因匯損而不如預期,天文游戲加上日、天文游戲韓掀起貿易戰傳出影響三星Note 10的生產計劃,沖擊股價表現,但泰碩( 3338 )下半年訂單動能持續強勁,內部對逐季成長展望保持樂觀,法人評估今年EPS可望來到3.5-4元區間水位。

此外,因躋身三星手機供應鏈,甚至Note 10熱板應用也有份,泰碩上月董事會決定辦理3億元的國內無擔??赊D換公司債(CB),因應產能的擴張,預計8月底之前可望募集完成。

泰碩第二季EPS 0.7元,其中6月EPS受到匯損影響僅0.07元,低于市場預期,導致股價重挫。而市場也傳出因日韓掀起貿易戰的因素,三星對新產品Note 10生產計劃也有變,估計將減產10%,不過,據悉泰碩下半年的生產計劃不變,手機的成長將是主要動能,身為中興5G基地臺散熱的主力供應商,在此產品線的成長也相當穩定,營運展望向上。


法人指出,5G商轉在即,全球電信商開始布建5G基地臺,泰碩今年3月開始陸續出貨給中國電信商,除對業績加分,因高毛利特性,有利獲利提升;加上旗艦型手機熱管/熱板應用持續增加,對泰碩今、明年的成長展望投下肯定票,第三季營運有望寫下新高紀錄。




【財訊快報記者王宜弘報導】金屬機殼大廠可成( 2474 )公告6月份獲利,你闖關因毛利率、你闖關營益率雙降,單月營業利益為4.36億元,稅前盈余則為23.89億元,均低于5月份的表現,第二季營業利益為15.12億元,較首季減少37.8%,同比衰退77.5%,續創新低紀錄。

第二季在匯率因素助陣之下,稅前盈余61.21億元,較上季大增98.5%,年減59.7%,較上季大幅回升。累計上半年營業利益39.01億元,稅前91.73億元,每股稅前11.87元。

可成因iPhone銷售不佳以及競爭因素,加上美中貿易戰干擾,今年業績陷入衰退,不過,6月營收來到單季最高水準,達62.85億元,月增15%,年減12.7%,第二季合併營收為160.68億元,季增1.7%,年減22.58%,累計上半年為318.79億元,同比衰退22.6%。


根據公告,6月可成自結獲利較5月下滑,主因為毛利率降至23%,營益率降至7%,不過業外貢獻帶動整體獲利提升。展望后市,法人認為,下半年旺季來臨,可成業績與毛利率將顯著攀升,而明年因5G手機需求訊號穿透度與散熱度要更好,將有利機殼ASP增加。





勇闖太空園游會6/16登場!16項天文游戲等你闖關

【財訊快報記者王宜弘報導】金屬機殼大廠可成( 2474 )第二季業績不如預期,勇闖太空園游會616儘管為部分外資降評,勇闖太空園游會616但股價表現持穩。臺系法人認為,可成谷底已過,本季受惠旺季,新iPhone與Macbook量產,帶動業績將大幅反彈,營收將季增36%,毛利率回升6個百分點。

可成週三(17日)股價在大盤下挫的格局之下相對抗跌,最低僅來到229元價位,跌幅為1.5%或3.5元。該公司今年因業績大幅下滑,在每月公告營收之際同步公告獲利,第二季合併營收160.7億元,季增1.7%,年減22.6%,上半年在匯兌收益挹注下EPS 11.87元。

不過,擺脫上半年的低迷,臺系法人認為,可成第三季起受惠于傳統旺季來臨,蘋果將在返校季推出的新MacBook Air,為首款100%由回收鋁合金製成的產品,可成因100%在自有工廠完成生產,競爭力佳,有助于Macbook業務的增長;此外,蘋果與高通訴訟案和解后,有利于iPhone明年推出5G產品,而iPhone外形設計改善升級,亦為可成利多。




【財訊快報記者王宜弘報導】金屬機殼廠應華( 5392 )合併旗下捷邦事宜週三(31日)正式上路,登場16項加上即將加入的日系汽車電子廠,登場16項新應華針對日系電動車、自駕車零組件市場的布局已大致完成,下半年電動車零組件業務占比將增至逾6成,成長引擎啟動。

不過,因部分換股套利賣壓出籠,應華週三股價呈現下跌逾3%的現象,週四(8/1)將除權息0.95元,現金與股票各半,下半年進入傳統旺季,加上套利賣壓漸消化,有助填權息。

新應華完成整併,股本擴大到15.9億元,除了捷邦之外,日系汽車零組件廠日本第一化成(IKKA)將近全資持有。由于捷邦長期供貨全球一線汽車零組件大廠德國Bosch電動工具機,去年下半年起取得Bosch針對ABS剎車模組的產品認證并開供貨,今年進一步放大。


此外,IKKA去年底完成EPB(電子煞車)模組認證,并有小量出貨,因EPB電子煞車模組在逐漸列為標配,日系訂單動能強,擴產需求殷切,預計IKKA將利用應華的廠區擴大產能。


至于即將併購的日本車用電子零組件業者,包括技術、業務能力均佳,除了ADAS先進駕駛輔助系統訂單加持之外,日系客戶的馬達零組件大單也已到手,今、明年的成長展望均佳,尤其對應華從機構跨足汽車電子領域,擴大客戶服務的範圍,競爭力提升助益大。




天文游戲

48 presentations and sessions to showcase Takeda鈥檚 hematology gene therapy pipeline and leading factor portfolio

CAMBRIDGE, Mass. & OSAKA, Japan -- (BUSINESS WIRE) --

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (鈥淭akeda鈥?, the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda鈥檚 pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.

鈥淎t Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without bleeds,鈥 said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. 鈥淲e look forward to presenting new data from PROPEL and important updates from our gene therapy and leading factor pipeline at ISTH 2019, showcasing our continued development and commitment in this area.鈥滭/p>

Importance of personalized prophylaxis in haemophilia
At ISTH 2019, Takeda will unveil new data from the Phase IIIb/IV PROPEL study 鈥 a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough Levels in subjects with severe hemophilia A.1 This data will build on results presented at the European Association of Haemophilia and Allied Disorders (EAHAD) 2019,2 to provide important insights into the role of personalized prophylaxis for enabling improved patient outcomes and bleed protection, in people living with hemophilia A.1

PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Hemophilia Optimizing Prophylaxis, ABSTRACT #OC 42.1; Monday, 08 July 2019, 14:45-16:00, Melbourne Room 2

Advancing the Promise of Gene Therapy in Hemophilia
Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient鈥檚 body to naturally produce a sufficient amount of the missing factor VIII or IX to alleviate bleeding episodes.3 Therefore, it may be possible to help convert a hemophilia patient鈥檚 bleeding phenotype from severe to mild or even normal in some cases.4 Takeda鈥檚 TAK-754 is our AAV FVIII gene therapy vector currently under investigation in a Phase I/II trial.

Notably, Takeda will showcase the following gene therapy data, in oral presentations:

Nonclinical pharmacology of TAK-748/SHP648 a novel factor IX (FIX) gene therapy vector in mice and rhesus monkeys. Gene Therapy Basic 1; Oral #OC 22.1 ; Sunday, 07 July 2019, 14:45-16:00, Melbourne Room 1Preexisting immunity against AAV8 and other AAV serotypes in healthy individuals and patients with hemophilia B. Gene Therapy Basic 2; Oral #OC31.4; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy (BAX335) reveals potential determinants of persistent transgene expression. Gene Therapy Basic 2; Oral #31.1; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1CTLA-4 IgGs - a powerful tool to enable re-administration in AAV8 gene therapy and to suppress anti-AAV8 T cell responses. Gene Therapy Basic 2; Oral #31.2; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1

Takeda will also present 33 other scientific data releases on the company鈥檚 recently acquired broad portfolio of treatments for bleeding disorders, in oral and poster presentations throughout ISTH. These will include:

6 Hematology Franchise Product Oral Presentations

FVIII: Development and characterization of an ELISA combined chromogenic assay for selective measurement of human FVIII activity in animal plasma matrix. Development of a formulation for oral delivery of FVIII via a robotic pill. The route of FVIII endocytosis by antigen-presenting cells determines the pattern of FVIII peptide-specific T cells activation.TAK-755: Efficacy of recombinant ADAMTS13 (TAK755) in a humanized mouse model for sickle cell disease.VEYVONDI: A new transgenic mouse model tolerant to human recombinant von Willebrand factor.ADYNOVATE PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: Safety and efficacy results from the phase 3 PROPEL Study

38 Poster Presentations

ADYNOVATE: A phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Clinical course and outcomes in patients with target joints. A retrospective, observational study using specialty pharmacy data of rurioctocog alfa pegol in clinical practice in the United States. High concentrations of polyethylene glycol (PEG) mediate vacuolation of human monocyte-derived macrophages in vitro without impairing their functionality. Outcomes with an extended prophylactic treatment schedule of rurioctocog alfa pegol in a phase 3b, open-label, multicenter, CONTINUATION study in previously treated patients with severe hemophilia A. Safety and immunogenicity results from a phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A.Gene Therapy: Factor VIII clotting and chromogenic activities for TAK-754 / SHP654, a clinical hemophilia A gene therapy candidate, using in vitro and in vivo assays. Biological relevance of low-titer anti-AAV8 neutralizing antibodies. Comparative integration site analysis of two factor IX (fix) gene therapy vectors with different vector design in mice. Evaluation of gene therapy mediated factor IX activity in selected in vivo test systems. Immunogenicity assessment of FVIII variants for 2nd generation gene therapy. Increased immunogenicity of CpG containing Adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression. Influence of obesity on gene therapy mediated factor IX expression in mice. Modulation of the Liver Immune Microenvironment by an Adeno-Associated Virus Serotype 8 Gene Therapy Vector. Nonclinical efficacy and toxicology evaluation of a human FVIII gene therapy vector (TAK-754/SHP654) in mice. Prevalence of preexisting immunity to adeno-associated virus (AAV) in adults with hemophilia: interim results from an international epidemiology study.ADVATE: AHEAD International and German Studies: Subgroup analysis of patients with moderate or severe hemophilia A receiving antihemophilic factor (recombinant) as Immune Tolerance Induction (ITI) therapy. Distinct antibody signatures in patients with FVIII inhibitors undergoing Immune Tolerance Induction (ITI) therapy. Interferon-gamma-inducible protein 10 levels are altered in patients with haemophilia with advanced haemophiliac arthropathy.FEIBA: Bispecific antibodies with light chain specificity for factor IXa and X improve thrombin generation in hemophilia A plasma. FVIII knock out mice treated with bypassing agent reveal thrombogenic activity when coadministered with bispecific-FIX/FX antibody. Real-world clinical management of patients with hemophila and inhibitors with aPCC: efficacy and safety data after 6 months in the 鈥淔EIBA Global Outcome Study (FEIBA GO)鈥? Safety of activated Prothrombin Complex Concentrate (aPCC) monotherapy in patients with haemophilia and inhibitors (PwHI): A systematic review.Hemophilia A/ FVIII: Characterisation of a new mouse model of haemophilia A developed using CRISPR/CAS9 technology. Pharmacokinetic and pharmacodynamic profiles of PSAylated and PEGylated rFVIII indicate consistent extended half-life potential in rodents and monkey. Adding the patient鈥檚 voice to a hemophilia specific goal menu to facilitate Goal Attainment Scaling: a qualitative study. Incidence and prevalence of diagnosed and undiagnosed hemophilia A and hemophilia B in select countries.TAK-755:Characterization of von Willebrand factor and ADAMTS13 in the Tim Townes mouse model of sickle cell disease. Cost of Illness (COI) of congenital Thrombotic Thrombocytopenic Purpura (cTTP) in the United States. Design of the first clinical study of recombinant ADAMTS13 for the acute treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP). Dose-dependent effects of recombinant ADAMTS13 (TAK755) on recovery in a humanized mouse model of sickle cell disease. Efficacy and PK/PD Relationship of Recombinant ADAMTS13 (TAK755) in a Humanized Mouse Model of Sickle Cell Disease. Extension of non-clinical safety margins for recombinant ADAMTS13 (TAK755) Feasibility study for subcutaneous route of administration of recombinant ADAMTS13 (TAK755). Recombinant ADAMTS13 (TAK755) can override the inhibitory effect of free hemoglobin on VWF multimer cleavage in vitro. Recombinant ADAMTS13 reduces the cell adhesion of blood from sickle cell disease mice under shear stress.VEYVONDI/ VONVENDI Determination of large and ultra-large multimers in recombinant human VWF (rVWF) and pharmacokinetic analyses in patients with Type 3 von Willebrand Disease (VWD). Infusion requirements in on demand treatment of bleeding events in von Willebrand Disease (VWD): an indirect treatment comparison between recombinant von Willebrand factor (VWF) and plasma derived VWF concentrates. Bleeding patterns in patients with von Willebrand Disease: An analysis of a US medical claims database.

About Hemophilia
Hemophilia is a challenging chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.5 Hemophilia A is more common than hemophilia B;5 hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.6

People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.7 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.5,8

About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real world experience. We have 70+ years driving innovation for patients9 and a broad portfolio of 11 products across nine hemophilia indications10. Our experience as leaders in hematology means we are well prepared to meet today鈥檚 needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

References

1

Klamroth R, Windyga J, Radulescu V, et al., PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Presented at ISTH 2019 (International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress. July 6-10, 2019. Abstract #A-1052-0038-01311.

2

Klamroth R, Windyga J, Radulescu V, et al., Results of a phase 3, randomized, multicenter study of RURIOCTOCOG ALFA PEGOL PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe Hemophilia A (propel study). Presented at European Association of Haematology and Allied Disorders (EAHAD) February 2019. Abstract #255.

3

National Institutes of Health: National Heart, Lung and Blood Institute. 鈥淕ene Therapy Helps Patients With Hemophilia B.鈥 National Heart, Lung and Blood Institute website. /uploads/2019-07-29/email-alerts Last Accessed April 2019.

4

Nathwani AC, Tuddenham EG, Rangarajan S, et al., Adenovirus-Associated Virus Vector鈥揗ediated Gene Transfer in Hemophilia B. N Engl J Med. 2011;365(25):2357鈥?365. Available at: /uploads/2019-07-29/ Last Accessed April 2019.

5

World Federation of Hemophilia. 鈥淲hat is hemophilia?鈥 World Federation of Hemophilia website. /uploads/2019-07-29/page.aspx Last Accessed April 2019.

6

World Federation of Hemophilia. Report on the Annual Global Survey 2017. World Federation of Hemophilia website. /uploads/2019-07-29/pdf-1714.pdf Last Accessed April 2019.

7

World Federation of Hemophilia. 鈥淎bout Bleeding Disorders: Treatment.鈥 World Federation of Hemophilia website. /uploads/2019-07-29/page.aspx Last Accessed April 2019.

8

National Hemophilia Foundation. 鈥淗emophilia A鈥? National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-A. Last Accessed April 2019.

9

Shire Website. Standards of Care for Hemophilia. Website: /uploads/2019-07-29/standards-of-care-for-hemophilia Last Accessed April 2019.

10

Shire Website. Product List. Website: /uploads/2019-07-29/product-list Last Accessed June 2019

View source version on businesswire.com: /uploads/2019-07-29/p

CONTACT:

Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933

Media outside Japan
Linda Calandra
linda.calandra1@takeda.com
+1 (617) 301-2092

你闖關

48 presentations and sessions to showcase Takeda鈥檚 hematology gene therapy pipeline and leading factor portfolio

CAMBRIDGE, Mass. & OSAKA, Japan -- (BUSINESS WIRE) --

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (鈥淭akeda鈥?, the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda鈥檚 pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.

鈥淎t Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without bleeds,鈥 said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. 鈥淲e look forward to presenting new data from PROPEL and important updates from our gene therapy and leading factor pipeline at ISTH 2019, showcasing our continued development and commitment in this area.鈥滭/p>

Importance of personalized prophylaxis in haemophilia
At ISTH 2019, Takeda will unveil new data from the Phase IIIb/IV PROPEL study 鈥 a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough Levels in subjects with severe hemophilia A.1 This data will build on results presented at the European Association of Haemophilia and Allied Disorders (EAHAD) 2019,2 to provide important insights into the role of personalized prophylaxis for enabling improved patient outcomes and bleed protection, in people living with hemophilia A.1

PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Hemophilia Optimizing Prophylaxis, ABSTRACT #OC 42.1; Monday, 08 July 2019, 14:45-16:00, Melbourne Room 2

Advancing the Promise of Gene Therapy in Hemophilia
Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient鈥檚 body to naturally produce a sufficient amount of the missing factor VIII or IX to alleviate bleeding episodes.3 Therefore, it may be possible to help convert a hemophilia patient鈥檚 bleeding phenotype from severe to mild or even normal in some cases.4 Takeda鈥檚 TAK-754 is our AAV FVIII gene therapy vector currently under investigation in a Phase I/II trial.

Notably, Takeda will showcase the following gene therapy data, in oral presentations:

Nonclinical pharmacology of TAK-748/SHP648 a novel factor IX (FIX) gene therapy vector in mice and rhesus monkeys. Gene Therapy Basic 1; Oral #OC 22.1 ; Sunday, 07 July 2019, 14:45-16:00, Melbourne Room 1Preexisting immunity against AAV8 and other AAV serotypes in healthy individuals and patients with hemophilia B. Gene Therapy Basic 2; Oral #OC31.4; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy (BAX335) reveals potential determinants of persistent transgene expression. Gene Therapy Basic 2; Oral #31.1; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1CTLA-4 IgGs - a powerful tool to enable re-administration in AAV8 gene therapy and to suppress anti-AAV8 T cell responses. Gene Therapy Basic 2; Oral #31.2; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1

Takeda will also present 33 other scientific data releases on the company鈥檚 recently acquired broad portfolio of treatments for bleeding disorders, in oral and poster presentations throughout ISTH. These will include:

6 Hematology Franchise Product Oral Presentations

FVIII: Development and characterization of an ELISA combined chromogenic assay for selective measurement of human FVIII activity in animal plasma matrix. Development of a formulation for oral delivery of FVIII via a robotic pill. The route of FVIII endocytosis by antigen-presenting cells determines the pattern of FVIII peptide-specific T cells activation.TAK-755: Efficacy of recombinant ADAMTS13 (TAK755) in a humanized mouse model for sickle cell disease.VEYVONDI: A new transgenic mouse model tolerant to human recombinant von Willebrand factor.ADYNOVATE PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: Safety and efficacy results from the phase 3 PROPEL Study

38 Poster Presentations

ADYNOVATE: A phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Clinical course and outcomes in patients with target joints. A retrospective, observational study using specialty pharmacy data of rurioctocog alfa pegol in clinical practice in the United States. High concentrations of polyethylene glycol (PEG) mediate vacuolation of human monocyte-derived macrophages in vitro without impairing their functionality. Outcomes with an extended prophylactic treatment schedule of rurioctocog alfa pegol in a phase 3b, open-label, multicenter, CONTINUATION study in previously treated patients with severe hemophilia A. Safety and immunogenicity results from a phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A.Gene Therapy: Factor VIII clotting and chromogenic activities for TAK-754 / SHP654, a clinical hemophilia A gene therapy candidate, using in vitro and in vivo assays. Biological relevance of low-titer anti-AAV8 neutralizing antibodies. Comparative integration site analysis of two factor IX (fix) gene therapy vectors with different vector design in mice. Evaluation of gene therapy mediated factor IX activity in selected in vivo test systems. Immunogenicity assessment of FVIII variants for 2nd generation gene therapy. Increased immunogenicity of CpG containing Adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression. Influence of obesity on gene therapy mediated factor IX expression in mice. Modulation of the Liver Immune Microenvironment by an Adeno-Associated Virus Serotype 8 Gene Therapy Vector. Nonclinical efficacy and toxicology evaluation of a human FVIII gene therapy vector (TAK-754/SHP654) in mice. Prevalence of preexisting immunity to adeno-associated virus (AAV) in adults with hemophilia: interim results from an international epidemiology study.ADVATE: AHEAD International and German Studies: Subgroup analysis of patients with moderate or severe hemophilia A receiving antihemophilic factor (recombinant) as Immune Tolerance Induction (ITI) therapy. Distinct antibody signatures in patients with FVIII inhibitors undergoing Immune Tolerance Induction (ITI) therapy. Interferon-gamma-inducible protein 10 levels are altered in patients with haemophilia with advanced haemophiliac arthropathy.FEIBA: Bispecific antibodies with light chain specificity for factor IXa and X improve thrombin generation in hemophilia A plasma. FVIII knock out mice treated with bypassing agent reveal thrombogenic activity when coadministered with bispecific-FIX/FX antibody. Real-world clinical management of patients with hemophila and inhibitors with aPCC: efficacy and safety data after 6 months in the 鈥淔EIBA Global Outcome Study (FEIBA GO)鈥? Safety of activated Prothrombin Complex Concentrate (aPCC) monotherapy in patients with haemophilia and inhibitors (PwHI): A systematic review.Hemophilia A/ FVIII: Characterisation of a new mouse model of haemophilia A developed using CRISPR/CAS9 technology. Pharmacokinetic and pharmacodynamic profiles of PSAylated and PEGylated rFVIII indicate consistent extended half-life potential in rodents and monkey. Adding the patient鈥檚 voice to a hemophilia specific goal menu to facilitate Goal Attainment Scaling: a qualitative study. Incidence and prevalence of diagnosed and undiagnosed hemophilia A and hemophilia B in select countries.TAK-755:Characterization of von Willebrand factor and ADAMTS13 in the Tim Townes mouse model of sickle cell disease. Cost of Illness (COI) of congenital Thrombotic Thrombocytopenic Purpura (cTTP) in the United States. Design of the first clinical study of recombinant ADAMTS13 for the acute treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP). Dose-dependent effects of recombinant ADAMTS13 (TAK755) on recovery in a humanized mouse model of sickle cell disease. Efficacy and PK/PD Relationship of Recombinant ADAMTS13 (TAK755) in a Humanized Mouse Model of Sickle Cell Disease. Extension of non-clinical safety margins for recombinant ADAMTS13 (TAK755) Feasibility study for subcutaneous route of administration of recombinant ADAMTS13 (TAK755). Recombinant ADAMTS13 (TAK755) can override the inhibitory effect of free hemoglobin on VWF multimer cleavage in vitro. Recombinant ADAMTS13 reduces the cell adhesion of blood from sickle cell disease mice under shear stress.VEYVONDI/ VONVENDI Determination of large and ultra-large multimers in recombinant human VWF (rVWF) and pharmacokinetic analyses in patients with Type 3 von Willebrand Disease (VWD). Infusion requirements in on demand treatment of bleeding events in von Willebrand Disease (VWD): an indirect treatment comparison between recombinant von Willebrand factor (VWF) and plasma derived VWF concentrates. Bleeding patterns in patients with von Willebrand Disease: An analysis of a US medical claims database.

About Hemophilia
Hemophilia is a challenging chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.5 Hemophilia A is more common than hemophilia B;5 hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.6

People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.7 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.5,8

About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real world experience. We have 70+ years driving innovation for patients9 and a broad portfolio of 11 products across nine hemophilia indications10. Our experience as leaders in hematology means we are well prepared to meet today鈥檚 needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

References

1

Klamroth R, Windyga J, Radulescu V, et al., PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Presented at ISTH 2019 (International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress. July 6-10, 2019. Abstract #A-1052-0038-01311.

2

Klamroth R, Windyga J, Radulescu V, et al., Results of a phase 3, randomized, multicenter study of RURIOCTOCOG ALFA PEGOL PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe Hemophilia A (propel study). Presented at European Association of Haematology and Allied Disorders (EAHAD) February 2019. Abstract #255.

3

National Institutes of Health: National Heart, Lung and Blood Institute. 鈥淕ene Therapy Helps Patients With Hemophilia B.鈥 National Heart, Lung and Blood Institute website. /uploads/2019-07-27/email-alerts Last Accessed April 2019.

4

Nathwani AC, Tuddenham EG, Rangarajan S, et al., Adenovirus-Associated Virus Vector鈥揗ediated Gene Transfer in Hemophilia B. N Engl J Med. 2011;365(25):2357鈥?365. Available at: /uploads/2019-07-27/ Last Accessed April 2019.

5

World Federation of Hemophilia. 鈥淲hat is hemophilia?鈥 World Federation of Hemophilia website. /uploads/2019-07-27/page.aspx Last Accessed April 2019.

6

World Federation of Hemophilia. Report on the Annual Global Survey 2017. World Federation of Hemophilia website. /uploads/2019-07-27/pdf-1714.pdf Last Accessed April 2019.

7

World Federation of Hemophilia. 鈥淎bout Bleeding Disorders: Treatment.鈥 World Federation of Hemophilia website. /uploads/2019-07-27/page.aspx Last Accessed April 2019.

8

National Hemophilia Foundation. 鈥淗emophilia A鈥? National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-A. Last Accessed April 2019.

9

Shire Website. Standards of Care for Hemophilia. Website: /uploads/2019-07-27/standards-of-care-for-hemophilia Last Accessed April 2019.

10

Shire Website. Product List. Website: /uploads/2019-07-27/product-list Last Accessed June 2019

View source version on businesswire.com: /uploads/2019-07-27/p

CONTACT:

Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933

Media outside Japan
Linda Calandra
linda.calandra1@takeda.com
+1 (617) 301-2092

勇闖太空園游會616

48 presentations and sessions to showcase Takeda鈥檚 hematology gene therapy pipeline and leading factor portfolio

CAMBRIDGE, Mass. & OSAKA, Japan -- (BUSINESS WIRE) --

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (鈥淭akeda鈥?, the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda鈥檚 pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.

鈥淎t Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without bleeds,鈥 said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. 鈥淲e look forward to presenting new data from PROPEL and important updates from our gene therapy and leading factor pipeline at ISTH 2019, showcasing our continued development and commitment in this area.鈥滭/p>

Importance of personalized prophylaxis in haemophilia
At ISTH 2019, Takeda will unveil new data from the Phase IIIb/IV PROPEL study 鈥 a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough Levels in subjects with severe hemophilia A.1 This data will build on results presented at the European Association of Haemophilia and Allied Disorders (EAHAD) 2019,2 to provide important insights into the role of personalized prophylaxis for enabling improved patient outcomes and bleed protection, in people living with hemophilia A.1

PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Hemophilia Optimizing Prophylaxis, ABSTRACT #OC 42.1; Monday, 08 July 2019, 14:45-16:00, Melbourne Room 2

Advancing the Promise of Gene Therapy in Hemophilia
Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient鈥檚 body to naturally produce a sufficient amount of the missing factor VIII or IX to alleviate bleeding episodes.3 Therefore, it may be possible to help convert a hemophilia patient鈥檚 bleeding phenotype from severe to mild or even normal in some cases.4 Takeda鈥檚 TAK-754 is our AAV FVIII gene therapy vector currently under investigation in a Phase I/II trial.

Notably, Takeda will showcase the following gene therapy data, in oral presentations:

Nonclinical pharmacology of TAK-748/SHP648 a novel factor IX (FIX) gene therapy vector in mice and rhesus monkeys. Gene Therapy Basic 1; Oral #OC 22.1 ; Sunday, 07 July 2019, 14:45-16:00, Melbourne Room 1Preexisting immunity against AAV8 and other AAV serotypes in healthy individuals and patients with hemophilia B. Gene Therapy Basic 2; Oral #OC31.4; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy (BAX335) reveals potential determinants of persistent transgene expression. Gene Therapy Basic 2; Oral #31.1; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1CTLA-4 IgGs - a powerful tool to enable re-administration in AAV8 gene therapy and to suppress anti-AAV8 T cell responses. Gene Therapy Basic 2; Oral #31.2; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1

Takeda will also present 33 other scientific data releases on the company鈥檚 recently acquired broad portfolio of treatments for bleeding disorders, in oral and poster presentations throughout ISTH. These will include:

6 Hematology Franchise Product Oral Presentations

FVIII: Development and characterization of an ELISA combined chromogenic assay for selective measurement of human FVIII activity in animal plasma matrix. Development of a formulation for oral delivery of FVIII via a robotic pill. The route of FVIII endocytosis by antigen-presenting cells determines the pattern of FVIII peptide-specific T cells activation.TAK-755: Efficacy of recombinant ADAMTS13 (TAK755) in a humanized mouse model for sickle cell disease.VEYVONDI: A new transgenic mouse model tolerant to human recombinant von Willebrand factor.ADYNOVATE PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: Safety and efficacy results from the phase 3 PROPEL Study

38 Poster Presentations

ADYNOVATE: A phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Clinical course and outcomes in patients with target joints. A retrospective, observational study using specialty pharmacy data of rurioctocog alfa pegol in clinical practice in the United States. High concentrations of polyethylene glycol (PEG) mediate vacuolation of human monocyte-derived macrophages in vitro without impairing their functionality. Outcomes with an extended prophylactic treatment schedule of rurioctocog alfa pegol in a phase 3b, open-label, multicenter, CONTINUATION study in previously treated patients with severe hemophilia A. Safety and immunogenicity results from a phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A.Gene Therapy: Factor VIII clotting and chromogenic activities for TAK-754 / SHP654, a clinical hemophilia A gene therapy candidate, using in vitro and in vivo assays. Biological relevance of low-titer anti-AAV8 neutralizing antibodies. Comparative integration site analysis of two factor IX (fix) gene therapy vectors with different vector design in mice. Evaluation of gene therapy mediated factor IX activity in selected in vivo test systems. Immunogenicity assessment of FVIII variants for 2nd generation gene therapy. Increased immunogenicity of CpG containing Adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression. Influence of obesity on gene therapy mediated factor IX expression in mice. Modulation of the Liver Immune Microenvironment by an Adeno-Associated Virus Serotype 8 Gene Therapy Vector. Nonclinical efficacy and toxicology evaluation of a human FVIII gene therapy vector (TAK-754/SHP654) in mice. Prevalence of preexisting immunity to adeno-associated virus (AAV) in adults with hemophilia: interim results from an international epidemiology study.ADVATE: AHEAD International and German Studies: Subgroup analysis of patients with moderate or severe hemophilia A receiving antihemophilic factor (recombinant) as Immune Tolerance Induction (ITI) therapy. Distinct antibody signatures in patients with FVIII inhibitors undergoing Immune Tolerance Induction (ITI) therapy. Interferon-gamma-inducible protein 10 levels are altered in patients with haemophilia with advanced haemophiliac arthropathy.FEIBA: Bispecific antibodies with light chain specificity for factor IXa and X improve thrombin generation in hemophilia A plasma. FVIII knock out mice treated with bypassing agent reveal thrombogenic activity when coadministered with bispecific-FIX/FX antibody. Real-world clinical management of patients with hemophila and inhibitors with aPCC: efficacy and safety data after 6 months in the 鈥淔EIBA Global Outcome Study (FEIBA GO)鈥? Safety of activated Prothrombin Complex Concentrate (aPCC) monotherapy in patients with haemophilia and inhibitors (PwHI): A systematic review.Hemophilia A/ FVIII: Characterisation of a new mouse model of haemophilia A developed using CRISPR/CAS9 technology. Pharmacokinetic and pharmacodynamic profiles of PSAylated and PEGylated rFVIII indicate consistent extended half-life potential in rodents and monkey. Adding the patient鈥檚 voice to a hemophilia specific goal menu to facilitate Goal Attainment Scaling: a qualitative study. Incidence and prevalence of diagnosed and undiagnosed hemophilia A and hemophilia B in select countries.TAK-755:Characterization of von Willebrand factor and ADAMTS13 in the Tim Townes mouse model of sickle cell disease. Cost of Illness (COI) of congenital Thrombotic Thrombocytopenic Purpura (cTTP) in the United States. Design of the first clinical study of recombinant ADAMTS13 for the acute treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP). Dose-dependent effects of recombinant ADAMTS13 (TAK755) on recovery in a humanized mouse model of sickle cell disease. Efficacy and PK/PD Relationship of Recombinant ADAMTS13 (TAK755) in a Humanized Mouse Model of Sickle Cell Disease. Extension of non-clinical safety margins for recombinant ADAMTS13 (TAK755) Feasibility study for subcutaneous route of administration of recombinant ADAMTS13 (TAK755). Recombinant ADAMTS13 (TAK755) can override the inhibitory effect of free hemoglobin on VWF multimer cleavage in vitro. Recombinant ADAMTS13 reduces the cell adhesion of blood from sickle cell disease mice under shear stress.VEYVONDI/ VONVENDI Determination of large and ultra-large multimers in recombinant human VWF (rVWF) and pharmacokinetic analyses in patients with Type 3 von Willebrand Disease (VWD). Infusion requirements in on demand treatment of bleeding events in von Willebrand Disease (VWD): an indirect treatment comparison between recombinant von Willebrand factor (VWF) and plasma derived VWF concentrates. Bleeding patterns in patients with von Willebrand Disease: An analysis of a US medical claims database.

About Hemophilia
Hemophilia is a challenging chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.5 Hemophilia A is more common than hemophilia B;5 hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.6

People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.7 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.5,8

About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real world experience. We have 70+ years driving innovation for patients9 and a broad portfolio of 11 products across nine hemophilia indications10. Our experience as leaders in hematology means we are well prepared to meet today鈥檚 needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

References

1

Klamroth R, Windyga J, Radulescu V, et al., PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Presented at ISTH 2019 (International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress. July 6-10, 2019. Abstract #A-1052-0038-01311.

2

Klamroth R, Windyga J, Radulescu V, et al., Results of a phase 3, randomized, multicenter study of RURIOCTOCOG ALFA PEGOL PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe Hemophilia A (propel study). Presented at European Association of Haematology and Allied Disorders (EAHAD) February 2019. Abstract #255.

3

National Institutes of Health: National Heart, Lung and Blood Institute. 鈥淕ene Therapy Helps Patients With Hemophilia B.鈥 National Heart, Lung and Blood Institute website. /uploads/2019-07-24/email-alerts Last Accessed April 2019.

4

Nathwani AC, Tuddenham EG, Rangarajan S, et al., Adenovirus-Associated Virus Vector鈥揗ediated Gene Transfer in Hemophilia B. N Engl J Med. 2011;365(25):2357鈥?365. Available at: /uploads/2019-07-24/ Last Accessed April 2019.

5

World Federation of Hemophilia. 鈥淲hat is hemophilia?鈥 World Federation of Hemophilia website. /uploads/2019-07-24/page.aspx Last Accessed April 2019.

6

World Federation of Hemophilia. Report on the Annual Global Survey 2017. World Federation of Hemophilia website. /uploads/2019-07-24/pdf-1714.pdf Last Accessed April 2019.

7

World Federation of Hemophilia. 鈥淎bout Bleeding Disorders: Treatment.鈥 World Federation of Hemophilia website. /uploads/2019-07-24/page.aspx Last Accessed April 2019.

8

National Hemophilia Foundation. 鈥淗emophilia A鈥? National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-A. Last Accessed April 2019.

9

Shire Website. Standards of Care for Hemophilia. Website: /uploads/2019-07-24/standards-of-care-for-hemophilia Last Accessed April 2019.

10

Shire Website. Product List. Website: /uploads/2019-07-24/product-list Last Accessed June 2019

View source version on businesswire.com: /uploads/2019-07-24/p

CONTACT:

Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933

Media outside Japan
Linda Calandra
linda.calandra1@takeda.com
+1 (617) 301-2092

登場16項

48 presentations and sessions to showcase Takeda鈥檚 hematology gene therapy pipeline and leading factor portfolio

CAMBRIDGE, Mass. & OSAKA, Japan -- (BUSINESS WIRE) --

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (鈥淭akeda鈥?, the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda鈥檚 pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.

鈥淎t Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without bleeds,鈥 said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. 鈥淲e look forward to presenting new data from PROPEL and important updates from our gene therapy and leading factor pipeline at ISTH 2019, showcasing our continued development and commitment in this area.鈥滭/p>

Importance of personalized prophylaxis in haemophilia
At ISTH 2019, Takeda will unveil new data from the Phase IIIb/IV PROPEL study 鈥 a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough Levels in subjects with severe hemophilia A.1 This data will build on results presented at the European Association of Haemophilia and Allied Disorders (EAHAD) 2019,2 to provide important insights into the role of personalized prophylaxis for enabling improved patient outcomes and bleed protection, in people living with hemophilia A.1

PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Hemophilia Optimizing Prophylaxis, ABSTRACT #OC 42.1; Monday, 08 July 2019, 14:45-16:00, Melbourne Room 2

Advancing the Promise of Gene Therapy in Hemophilia
Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient鈥檚 body to naturally produce a sufficient amount of the missing factor VIII or IX to alleviate bleeding episodes.3 Therefore, it may be possible to help convert a hemophilia patient鈥檚 bleeding phenotype from severe to mild or even normal in some cases.4 Takeda鈥檚 TAK-754 is our AAV FVIII gene therapy vector currently under investigation in a Phase I/II trial.

Notably, Takeda will showcase the following gene therapy data, in oral presentations:

Nonclinical pharmacology of TAK-748/SHP648 a novel factor IX (FIX) gene therapy vector in mice and rhesus monkeys. Gene Therapy Basic 1; Oral #OC 22.1 ; Sunday, 07 July 2019, 14:45-16:00, Melbourne Room 1Preexisting immunity against AAV8 and other AAV serotypes in healthy individuals and patients with hemophilia B. Gene Therapy Basic 2; Oral #OC31.4; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy (BAX335) reveals potential determinants of persistent transgene expression. Gene Therapy Basic 2; Oral #31.1; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1CTLA-4 IgGs - a powerful tool to enable re-administration in AAV8 gene therapy and to suppress anti-AAV8 T cell responses. Gene Therapy Basic 2; Oral #31.2; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1

Takeda will also present 33 other scientific data releases on the company鈥檚 recently acquired broad portfolio of treatments for bleeding disorders, in oral and poster presentations throughout ISTH. These will include:

6 Hematology Franchise Product Oral Presentations

FVIII: Development and characterization of an ELISA combined chromogenic assay for selective measurement of human FVIII activity in animal plasma matrix. Development of a formulation for oral delivery of FVIII via a robotic pill. The route of FVIII endocytosis by antigen-presenting cells determines the pattern of FVIII peptide-specific T cells activation.TAK-755: Efficacy of recombinant ADAMTS13 (TAK755) in a humanized mouse model for sickle cell disease.VEYVONDI: A new transgenic mouse model tolerant to human recombinant von Willebrand factor.ADYNOVATE PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: Safety and efficacy results from the phase 3 PROPEL Study

38 Poster Presentations

ADYNOVATE: A phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Clinical course and outcomes in patients with target joints. A retrospective, observational study using specialty pharmacy data of rurioctocog alfa pegol in clinical practice in the United States. High concentrations of polyethylene glycol (PEG) mediate vacuolation of human monocyte-derived macrophages in vitro without impairing their functionality. Outcomes with an extended prophylactic treatment schedule of rurioctocog alfa pegol in a phase 3b, open-label, multicenter, CONTINUATION study in previously treated patients with severe hemophilia A. Safety and immunogenicity results from a phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A.Gene Therapy: Factor VIII clotting and chromogenic activities for TAK-754 / SHP654, a clinical hemophilia A gene therapy candidate, using in vitro and in vivo assays. Biological relevance of low-titer anti-AAV8 neutralizing antibodies. Comparative integration site analysis of two factor IX (fix) gene therapy vectors with different vector design in mice. Evaluation of gene therapy mediated factor IX activity in selected in vivo test systems. Immunogenicity assessment of FVIII variants for 2nd generation gene therapy. Increased immunogenicity of CpG containing Adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression. Influence of obesity on gene therapy mediated factor IX expression in mice. Modulation of the Liver Immune Microenvironment by an Adeno-Associated Virus Serotype 8 Gene Therapy Vector. Nonclinical efficacy and toxicology evaluation of a human FVIII gene therapy vector (TAK-754/SHP654) in mice. Prevalence of preexisting immunity to adeno-associated virus (AAV) in adults with hemophilia: interim results from an international epidemiology study.ADVATE: AHEAD International and German Studies: Subgroup analysis of patients with moderate or severe hemophilia A receiving antihemophilic factor (recombinant) as Immune Tolerance Induction (ITI) therapy. Distinct antibody signatures in patients with FVIII inhibitors undergoing Immune Tolerance Induction (ITI) therapy. Interferon-gamma-inducible protein 10 levels are altered in patients with haemophilia with advanced haemophiliac arthropathy.FEIBA: Bispecific antibodies with light chain specificity for factor IXa and X improve thrombin generation in hemophilia A plasma. FVIII knock out mice treated with bypassing agent reveal thrombogenic activity when coadministered with bispecific-FIX/FX antibody. Real-world clinical management of patients with hemophila and inhibitors with aPCC: efficacy and safety data after 6 months in the 鈥淔EIBA Global Outcome Study (FEIBA GO)鈥? Safety of activated Prothrombin Complex Concentrate (aPCC) monotherapy in patients with haemophilia and inhibitors (PwHI): A systematic review.Hemophilia A/ FVIII: Characterisation of a new mouse model of haemophilia A developed using CRISPR/CAS9 technology. Pharmacokinetic and pharmacodynamic profiles of PSAylated and PEGylated rFVIII indicate consistent extended half-life potential in rodents and monkey. Adding the patient鈥檚 voice to a hemophilia specific goal menu to facilitate Goal Attainment Scaling: a qualitative study. Incidence and prevalence of diagnosed and undiagnosed hemophilia A and hemophilia B in select countries.TAK-755:Characterization of von Willebrand factor and ADAMTS13 in the Tim Townes mouse model of sickle cell disease. Cost of Illness (COI) of congenital Thrombotic Thrombocytopenic Purpura (cTTP) in the United States. Design of the first clinical study of recombinant ADAMTS13 for the acute treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP). Dose-dependent effects of recombinant ADAMTS13 (TAK755) on recovery in a humanized mouse model of sickle cell disease. Efficacy and PK/PD Relationship of Recombinant ADAMTS13 (TAK755) in a Humanized Mouse Model of Sickle Cell Disease. Extension of non-clinical safety margins for recombinant ADAMTS13 (TAK755) Feasibility study for subcutaneous route of administration of recombinant ADAMTS13 (TAK755). Recombinant ADAMTS13 (TAK755) can override the inhibitory effect of free hemoglobin on VWF multimer cleavage in vitro. Recombinant ADAMTS13 reduces the cell adhesion of blood from sickle cell disease mice under shear stress.VEYVONDI/ VONVENDI Determination of large and ultra-large multimers in recombinant human VWF (rVWF) and pharmacokinetic analyses in patients with Type 3 von Willebrand Disease (VWD). Infusion requirements in on demand treatment of bleeding events in von Willebrand Disease (VWD): an indirect treatment comparison between recombinant von Willebrand factor (VWF) and plasma derived VWF concentrates. Bleeding patterns in patients with von Willebrand Disease: An analysis of a US medical claims database.

About Hemophilia
Hemophilia is a challenging chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.5 Hemophilia A is more common than hemophilia B;5 hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.6

People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.7 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.5,8

About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real world experience. We have 70+ years driving innovation for patients9 and a broad portfolio of 11 products across nine hemophilia indications10. Our experience as leaders in hematology means we are well prepared to meet today鈥檚 needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

References

1

Klamroth R, Windyga J, Radulescu V, et al., PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Presented at ISTH 2019 (International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress. July 6-10, 2019. Abstract #A-1052-0038-01311.

2

Klamroth R, Windyga J, Radulescu V, et al., Results of a phase 3, randomized, multicenter study of RURIOCTOCOG ALFA PEGOL PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe Hemophilia A (propel study). Presented at European Association of Haematology and Allied Disorders (EAHAD) February 2019. Abstract #255.

3

National Institutes of Health: National Heart, Lung and Blood Institute. 鈥淕ene Therapy Helps Patients With Hemophilia B.鈥 National Heart, Lung and Blood Institute website. /uploads/2019-07-20/email-alerts Last Accessed April 2019.

4

Nathwani AC, Tuddenham EG, Rangarajan S, et al., Adenovirus-Associated Virus Vector鈥揗ediated Gene Transfer in Hemophilia B. N Engl J Med. 2011;365(25):2357鈥?365. Available at: /uploads/2019-07-20/ Last Accessed April 2019.

5

World Federation of Hemophilia. 鈥淲hat is hemophilia?鈥 World Federation of Hemophilia website. /uploads/2019-07-20/page.aspx Last Accessed April 2019.

6

World Federation of Hemophilia. Report on the Annual Global Survey 2017. World Federation of Hemophilia website. /uploads/2019-07-20/pdf-1714.pdf Last Accessed April 2019.

7

World Federation of Hemophilia. 鈥淎bout Bleeding Disorders: Treatment.鈥 World Federation of Hemophilia website. /uploads/2019-07-20/page.aspx Last Accessed April 2019.

8

National Hemophilia Foundation. 鈥淗emophilia A鈥? National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-A. Last Accessed April 2019.

9

Shire Website. Standards of Care for Hemophilia. Website: /uploads/2019-07-20/standards-of-care-for-hemophilia Last Accessed April 2019.

10

Shire Website. Product List. Website: /uploads/2019-07-20/product-list Last Accessed June 2019

View source version on businesswire.com: /uploads/2019-07-20/p

CONTACT:

Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933

Media outside Japan
Linda Calandra
linda.calandra1@takeda.com
+1 (617) 301-2092

10部共12本日本漫畫作品 將于臺灣樂天Kobo電子書平臺開始發售

利用高效率翻譯軟件「Manga100%? Engine」更迅速提供漫畫給Kobo讀者

臺灣臺北2019年5月8日 /美通社/ --?日本株式會社I.Meisters(總部位置:天文游戲東京都新宿區),天文游戲于2019年4月5日,將在臺灣的電子書平臺(中文名稱:「樂天Kobo電子書商店」URL:http://tw.kobo.com/)發布利用本社『Manga 100%?Engine』翻譯,海外尚未發售的日本漫畫繁體中文版電子書,目的是讓臺灣漫畫迷可以直接于樂天Kobo電子書平臺購買,利用手機、平板及電子書閱讀器,閱讀更多更豐富未在日本海外發售的漫畫作品。

日本株式會社I.Meisters于2018年5月25日,與樂天株式會社(總部位置:東京世田谷區,以下稱「樂天」)旗下公司Rakuten Kobo Inc.(總部位置:加拿大.多倫多市、以下稱「Kobo」)簽訂協議并合作積極發布尚未在日本以外發售的漫畫作品。

?作為最初公開的系列作品,于2019年4月5日,將以金谷裕老師的「沒干勁拳王」、「雪白之刀」、「無影」等三作品為首,發布10部共12本的繁中電子版日本漫畫,未來也將向讀者提供更多尚未在海外發售的作品。

I. Meisters計劃發展名為『Manga 100%?』的平臺。此平臺為外國讀者提供各種翻譯版漫畫,其核心思想為快速翻譯漫畫并結合電子化的最先進演算法開發翻譯及數據轉換系統『Manga 100%?Engine』。

這次與樂天Kobo電子書平臺的合作,本社利用獨自開發的高速且高效率翻譯軟件『Manga 100%?Engine』電子化與翻譯技術,讓更多日本漫畫可以快速且便利地推廣到臺灣市場,并且透過此次的合作,獲得Rakuten Kobo臺灣區營運部長周立涵先生的肯定:「我們期待透過與I.Meisters的合作,為臺灣市場引進更多日本原創漫畫,提供給臺灣讀者更多高品質的漫畫選擇?!?/p>

今后為了向日本以外的讀者提供更多的日本漫畫,我們會繼續活用『Manga 100%?Engine』的技術,提供平臺并持續開發系統。提供書籍電子化、翻譯、編輯、出版及合同諮詢等業務,促進日本漫畫在世界各地的發展。

【部分發售作品】

部分發售作品
部分發售作品

關于【樂天Kobo電子書商店】

樂天Kobo電子書,成立于2009年,總部位于加拿大多倫多,隸屬日本樂天集團旗下,于2016年9月進軍臺灣市場,并積極與出版社合作,將繁體中文電子書籍,透過樂天Kobo銷售給臺灣以及全球的華文讀者。

樂天Kobo全球用戶超過3000萬,服務遍及190個國家和地區,提供超過600萬本中、外文電子書籍及雜誌。其中繁體中文藏書量成長至今已突破8萬冊,良好的數位閱讀體驗,更吸引讀者加入行動閱讀的行列。樂天Kobo始終相信,愛看書的人應自由地在任何載具閱讀每一本書,只要開啟手機、平板、電子書閱讀器,就能隨時隨地享受閱讀的樂趣。

關于【日本株式會社I.Meisters】

日本株式會社I.Meisters,以「把日本的文化產業、技術、人才連接世界,使世界變得更幸福?!篂樽谥?,把漫畫和游戲(圖形)×以國內及海外為軸心展開事業。

【株式會社I.Meisters?公司概要】
公司名稱:株式會社I.Meisters (英文名稱:I. Meisters Inc. )
成立: 2016年7月
資本金:3,000,000円
代表者:代表取締役 今井星(Sei Imai)
公司地址:160-0004 東京都新宿區四谷1-20-2 佳作大廈7樓
URL :? http://i-meisters.com/

圖片 - https://photos.prnasia.com/prnh/20190426/2447988-1

相關鏈接 :

http://tw.kobo.com/

(責任編輯:搬手)

推薦文章
熱點閱讀
亚洲国产高清在线观看视频,岬奈奈美免费在线观看,飞空精品影院